Stock Screener App

Frei -

Installieren

2.88

25.76% 0.59

Vorhandelsmarkt: 2.69 -0.19 -6.60%

Gri Bio Inc (GRI)

Überblick Nachrichten Preisverlauf Forum Prognose

Gri Bio Inc Aktie (GRI) Neueste Nachrichten

What Put GRI Bio (NASDAQ:GRI) on the Nasdaq Composite Radar? - Kalkine Media

GRI Bio Surges As Phase 2a IPF Drug Data Nears - StocksToTrade

GRI Bio Jumps As Positive IPF Drug Data Nears ERS Stage - timothysykes.com

GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF - HCPLive

GRI Bio Surges As Phase 2a IPF Data Near ERS Reveal - timothysykes.com

GRI Bio Company Profile & Introduction - Moomoo

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

GRI|GRI Bio Inc|Price:2.880|Chg%:+0.590 - TradingKey

GRI Bio will present data on its once-daily oral drug in Barcelona this September - Stock Titan

GRI Bio Featured in "Why Now" On-Demand Video Webcast - Yahoo Finance

OSRH Stock Price and Chart — OTC:OSRH - TradingView

GRI Bio Price Target Cut to $27.00/Share From $32.00 by Ascendiant Capital - Moomoo

GRI Bio to present Phase 2a IPF drug data at ERS Congress - Investing.com Canada

GRI (GRI) EPS and Revenue: Reported EPS Misses Expectations in the Latest Reading; Market Move: The Stock Loses 3.47% in the Current UpdateEarnings Forecast Report - vinanet.vn

GRI Bio Inc. (GRI) Climbs 3.6% to $1.73 as Buyers Defend Key SupportWyckoff Accumulation - vinanet.vn

GRI Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss of $1.61 Per Share, Yet Stock Closes Up 3.59 - vinanet.vn

GRI Q1 2026 Earnings: EPS Falls Sharply Short of Estimates as Shares Slide 5.65%Earnings Forecast Report - vinanet.vn

GRI Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView

GRI Bio, Inc. 2Q 2026: Net income $(1.64)M, EPS $(0.91) — 10-Q Summary - TradingView

Form 10-Q GRI Bio, Inc. For: Jun 30 - StreetInsider

GRI Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

GRI Bio (GRI) investors disclose 4.99% stake capped by warrant blockers - Stock Titan

GRI Q2'26 Earnings: revenue estimate is 0 USD - TradingView

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

GRI Bio Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView

GRI Bio (GRI) Jumps 15.65% to $1.70 — Breakout Above $1.78 Could Extend RallyHigh Low Breadth - dars.gov.et

GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

GRI Bio Inc. (NASDAQ: GRI) Share Price, GRI Stock News, GRI Share Price & Updates - kalkine.ca

GRI Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage BurnBuyback Announcement Report - vinanet.vn

GRI Bio Inc (GRI) Cash Flow - TradingKey

GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey

GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

GRI|GRI Bio Inc|Price:1.420|Chg%:-0.030 - TradingKey

GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com

GRI Bio Inc (GRI) Income Statement - TradingKey

Gri Bio, Inc. (GRI) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks

TradingKey - TradingKey

GRI Bio Inc (GRI) Institutional Confidence - TradingKey

GRI Bio, Inc. Revenue Breakdown – NASDAQ:GRI - TradingView

GRI Bio Inc (GRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Price to sales forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView

CHGA Stock Price and Chart — NASDAQ:CHGA - TradingView

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

GRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin as Pre‑Revenue Biotech Faces Increased CostsReturn On Capital - Vinanet

GRI Bio Inc. (GRI) Retreats 3.23% as Shares Test Support Near $1.42Price Surge Stocks - dars.gov.et

GRI Q1 2026 Earnings: Wider-than-Expected Loss on No RevenueEarnings Analysis - vinanet.vn

GRI Q1 2026 Earnings: EPS Misses Estimates by 76%, No Revenue ReportedReturn On Capital - vinanet.vn

GRI Bio Inc. (GRI) Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue StageMargin Guidance - dars.gov.et

GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by 76%, Stock Rises 2.6% Amid Strategic Progress - Bölüm Sonu Canavarı

GRI Bio Inc. (GRI) Q1 2026 Earnings: Wider-than-Expected Loss Exceeds Estimates on Pre-Revenue StatusTech Earnings Analysis - dars.gov.et

Price to earnings forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView

GRI Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Revenue AbsentSubscription Growth Report - dars.gov.et

GRI Bio Inc. (GRI) Declines Over 8%, Approaching Critical Support at $1.73Liquidity Order Flow - dars.gov.et

GRI Q1 2026 Earnings: EPS Misses Estimates by 76%, Shares Slide 8%Mid-Term Outlook - dars.gov.et

Price to sales forward of GRI Bio, Inc. – BOATS:GRI - TradingView

Enterprise value to revenue forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView

GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by over 76% as Pre-Revenue Biotech Continues DevelopmentInterim Report - dars.gov.et

Enterprise value to EBIT forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView

Price to earnings forward of GRI Bio, Inc. – BOATS:GRI - TradingView

Enterprise value to EBIT forward of GRI Bio, Inc. – BOATS:GRI - TradingView

Enterprise value to EBITDA forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView

GRI Q1 2026 Earnings: EPS Miss Widens Losses as Pre-Revenue Biotech Stock RalliesProfit Margin Analysis - DonanımHaber

ADTX Stock Price and Chart — OTC:ADTX - TradingView

GRI Bio, Inc. Actuals & Estimates (NASDAQ:GRI) - TradingView

GRI Forecast — Price Target — Prediction for 2027 - TradingView

GRI Bio Inc. (GRI) Rallies 3.8% as Momentum Builds Above Key SupportBollinger Expansion - dars.gov.et

GRI Bio Inc (GRI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

GRI Bio Inc. (GRI) Edges Lower Near Support Amid Biotech Sector VolatilityDemand Zone - dars.gov.et

GRI Bio Inc. (GRI) Faces Steep Decline as Shares Test Key Support LevelsEarly Entry Signals - dars.gov.et

GRI Bio Secures FDA Orphan Drug Status for IPF - TipRanks

BNTX

$103.76

0.86%

INSM

$126.29

0.31%

RPRX

$63.96

0.13%

ALNY

$266.11

0.61%

ONC

$358.26

1.22%

RVMD

$210.02

0.40%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters